SEARCH

SEARCH BY CITATION

References

  • Anderson, K.C. (2003) The role of immunomodulatory drugs in multiple myeloma. Seminars in Hematology, 40, 2332.
  • Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New England Journal of Medicine, 335, 9197.
  • D'Amato, R.J., Loughnan, M.S., Flynn, E. & Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 91, 40824085.
  • Damiano, J.S., Cress, A.E., Hazlehurst, L.A., Shtil, A.A. & Dalton, W.S. (1999) Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 93, 16581667.
  • Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S.P., Richardson, P.G., Schlossman, R.L., Morgan, G.J., Muller, G.W., Stirling, D.I. & Anderson, K.C. (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98, 210216.
  • Dredge, K., Marriott, J.B. & Dalgleish, A.G. (2002) Immunological effects of thalidomide and its chemical and functional analogs. Critical Reviews in Immunology, 22, 425437.
  • Haslett, P.A., Corral, L.G., Albert, M. & Kaplan, G. (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. Journal of Experimental Medicine, 187, 18851892.
  • Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F.E., Tai, Y.T., Treon, S.P., Lin, B., Schlossman, R.L., Richardson, P., Muller, G., Stirling, D.I. & Anderson, K.C. (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96, 29432950.
  • Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., Adams, J. & Anderson, K.C. (2002) NF-kappa B as a therapeutic target in multiple myeloma. Journal of Biological Chemistry, 277, 1663916647.
  • Jemal, A., Tiwari, R.C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E.J. & Thun, M.J. (2004) Cancer statistics, 2004. CA: A Cancer Journal for Clinicians, 54, 829.
  • Kumar, S., Gertz, M.A., Dispenzieri, A., Lacy, M.Q., Geyer, S.M., Iturria, N.L., Fonseca, R., Hayman, S.R., Lust, J.A., Kyle, R.A., Greipp, P.R., Witzig, T.E. & Rajkumar, S.V. (2003) Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clinic Proceedings, 78, 3439.
  • Kumar, S., Witzig, T.E., Dispenzieri, A., Lacy, M.Q., Wellik, L.E., Fonseca, R., Lust, J.A., Gertz, M.A., Kyle, R.A., Greipp, P.R. & Rajkumar, S.V. (2004) Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia, 18, 624627.
  • Kumar, S., Raje, N., Hideshima, T., Ishitsuka, K., Roccaro, A., Shiraishi, N., Hamasaki, M., Yasui, H., Munshi, N.C., Richardson, P., Figg, W.D. & Anderson, K.C. (2005) Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs. Leukemia, 19, 12531261.
  • Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Richardson, P.G., Hideshima, T., Munshi, N.C., Treon, S.P. & Anderson, K.C. (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 99, 45254530.
  • Rajkumar, S.V., Hayman, S., Gertz, M.A., Dispenzieri, A., Lacy, M.Q., Greipp, P.R., Geyer, S., Iturria, N., Fonseca, R., Lust, J.A., Kyle, R.A. & Witzig, T.E. (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of Clinical Oncology, 20, 43194323.
  • Richardson, P., Hideshima, T. & Anderson, K. (2002a) Thalidomide: emerging role in cancer medicine. Annual Review of Medicine, 53, 629657.
  • Richardson, P.G., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L.P., Doss, D., Kelly, K., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J.J., Chauhan, D., Balinski, K., Zeldis, J. & Anderson, K.C. (2002b) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 30633067.
  • Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. & Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 15651571.